0000000000850180

AUTHOR

Giorgia Saia

showing 7 related works from this author

Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary

2020

medicine.medical_specialtyBisphosphonate-associated osteonecrosis of the jawOncology (nursing)business.industryHealth PolicyMEDLINEGuidelinemedicine.diseaseClinical PracticeOncologymascc isoo ascoo mrojHumansMedicineBisphosphonate-Associated Osteonecrosis of the JawbusinessOsteonecrosis of the jawIntensive care medicineJCO Oncology Practice
researchProduct

RE: MEDICATION-RELATED OSTEONECROSIS OF THE JAW (MRONJ)

2021

OrthodonticsOtorhinolaryngologybusiness.industrySection (typography)medicineMEDLINESurgeryOral SurgeryOsteonecrosis of the jawmedicine.diseasebusinessJournal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
researchProduct

Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease

2014

AbstractManagement of osteonecrosis of the jaw associated with antiresorptive agents is challenging, and outcomes are unpredictable. The severity of disease is the main guide to management, and can help to predict prognosis. Most available staging systems for osteonecrosis, including the widely-used American Association of Oral and Maxillofacial Surgeons (AAOMS) system, classify severity on the basis of clinical and radiographic findings. However, clinical inspection and radiography are limited in their ability to identify the extent of necrotic bone disease compared with computed tomography (CT). We have organised a large multicentre retrospective study (known as MISSION) to investigate th…

AdultMaleCutaneous FistulaSettore MED/50 - Scienze Tecniche Mediche ApplicateDental Fistulastaging system; bisphosphonate; computed tomography; aaoms; osteonecrosis of the jaw; antiresorptive agentsAAOMSAntiresorptive agentSettore MED/29 - Chirurgia MaxillofaccialeAAOMS Antiresorptive agents Bisphosphonate Computed tomography Osteonecrosis of the jaw Staging systemBronj; AAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemSettore MED/28 - Malattie OdontostomatologicheMandibular FracturesBronjOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAlveolar ProcessHumansBisphosphonateMandibular DiseasesComputed tomographyAgedRetrospective StudiesAged 80 and overSuppurationBone Density Conservation AgentsOsteonecrosis of the jawPatient AcuityAntiresorptive agentsCone-Beam Computed TomographyMiddle AgedStaging systemMaxillary DiseasesPhenotypeOtorhinolaryngologyTooth ExtractionBisphosphonate-Associated Osteonecrosis of the JawDrug Therapy CombinationFemaleSurgeryOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemOral SurgeryTomography X-Ray ComputedTomography Spiral ComputedOsteosclerosis
researchProduct

BRONJ in patients with rheumatoid arthritis: A multicenter case series

2016

Objective: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of various medications (bisphosphonates, anti-resorptive, and anti-angiogenic drugs). ONJ pathogenesis is still unclear although some risk factors have been recognized. Of these, rheumatoid arthritis (RA) has been hypothesized as a potential risk factor for developing ONJ. This observational study will describe a multicenter case series of patients affected with RA and ONJ, and it will attempt to evaluate the association between features of ONJ and pharmacological, systemic, and site variables. Methods: Demographic, pharmacological, and clinical data from 18 RA patients with ONJ were collected and registered fr…

Malemedicine.medical_specialtymedicine.medical_treatmentOsteoporosisONJArthritis Rheumatoid03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansBisphosphonateONJ; Bisphosphonate; Denosumab; Jaw; Osteonecrosis; Osteoporosis; Rheumatoid arthritis; Dentistry (all); Otorhinolaryngology2734 Pathology and Forensic MedicineRheumatoid arthritisAdverse effectGeneral DentistryRheumatoid arthritiAgedBisphosphonate-associated osteonecrosis of the jawbusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineOsteoporosiOsteonecrosis030206 dentistryBisphosphonateMiddle Agedmedicine.diseaseSurgeryDenosumabOtorhinolaryngologyJaw030220 oncology & carcinogenesisRheumatoid arthritisOsteonecrosiDentistry (all)OsteoporosisMethotrexateBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multic…

2015

Osteonecrosis of the jaw (ONJ) associated with the use of bisphosphonates has been rarely reported in metastatic renal cell cancer (RCC) patients. Since the introduction of combined therapies consisting of nitrogen-containing bisphosphonates (NBPs) and targeted agents, an increasing number of RCC patients were reported to develop ONJ, suggesting that therapeutic angiogenesis suppression might increase the risk of ONJ in NBPs users. We performed a multicenter retrospective study and reviewed literature data to assess the occurrence and to investigate the nature of ONJ in RCC patients taking NBPs and targeted agents. Nine Italian Centers contributed to the data collection. Patients with expos…

MaleOncologyIndolesAngiogenesis InhibitorsPyrroleBevacizumab; m-TOR inhibitor; Sorafenib; Sunitinib; Zoledronic acidRetrospective StudieAntineoplastic Combined Chemotherapy ProtocolsSunitinibAged 80 and overDiphosphonatesSunitinibImidazolesOsteonecrosisKidney NeoplasmMiddle AgedSorafenibKidney NeoplasmsBevacizumabDiphosphonateItalyOncologyOsteonecrosiFemaleAngiogenesis InhibitorHumanmedicine.drugSorafenibmedicine.medical_specialtyBevacizumab; m-TOR inhibitor; Sorafenib; Sunitinib; Zoledronic acid; Aged; Aged 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Indoles; Italy; Jaw; Kidney Neoplasms; Male; Middle Aged; Osteonecrosis; Pyrroles; Retrospective Studies; Oncology; UrologyBevacizumabUrologyInternal medicinemedicineHumansPyrrolesIn patientMetastatic renal cell cancerImidazoleCarcinoma Renal CellZoledronic acidAgedRetrospective StudiesAntineoplastic Combined Chemotherapy Protocolbusiness.industryRetrospective cohort studymedicine.diseasem-TOR inhibitorSurgeryZoledronic acidJawIndolebusinessOsteonecrosis of the jaw
researchProduct

Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed

2014

AbstractRecent data suggest that the traditional definition of bisphosphonate-associated osteonecrosis of the jaw (ONJ) may exclude patients who present with the non-exposed variant of the condition. To test the hypothesis that a proportion of patients with ONJ remain undiagnosed because their symptoms do not conform to the traditional case definition, we did a secondary analysis of data from MISSION (Multicentre study on phenotype, definition and classification of osteonecrosis of the jaws associated with bisphosphonates), a cross-sectional study of a large population of patients with bisphosphonate-associated ONJ who were recruited in 13 European centres. Patients with exposed and non-exp…

MaleDelayed DiagnosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAntineoplastic AgentsOsteonecrosis; Jawbones; BisphosphonatesOsteonecrosis; Jawbones;BisphosphonatesSettore MED/29 - Chirurgia MaxillofaccialeSettore MED/28 - Malattie OdontostomatologicheOsteonecrosis; Jawbones; Bisphosphonates;JawbonesBisphosphonateHumansDiagnostic Errorsosteonecrosis; jawbones; bisphosphonatesPeriodontal DiseasesAgedPain MeasurementBone Density Conservation AgentsOsteonecrosisBisphosphonatesMiddle AgedCross-Sectional StudiesPhenotypeOtorhinolaryngologyTooth DiseasesTooth ExtractionOsteonecrosiOsteoporosisSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOral SurgeryJawbone
researchProduct

Comment on “Medication-Related Osteonecrosis of the Jaw (MRONJ)” by Elie M. Ferneini in the Section “Simply Put: JOMS Information for Patients”

2021

We read with great interest the contribute to the section “Simply Put: JOMS Information for Patients” named “Medication-Related Osteonecrosis of the Jaw (MRONJ)” by Elie M. Ferneini.

Comment medication-related osteonecrosis of the jaw mronj
researchProduct